PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report-Reference-Cited by-同舟云学术

PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report

Published:2016-11-15 Issue:1 Volume:4 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Nagasaka Misako,Zaki Mark,Kim Harold,Raza S. Naweed,Yoo George,Lin Ho-sheng,Sukari Ammar

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-016-0187-0.pdf

Reference9 articles.

1. U.S. Food and Drug Administration. Approved Drugs: pembrolizumab (KEYTRUDA). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm515627.htm . Accessed 23 Sept 2016.

2. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–65.

3. Mehra R, Seiwert TY, Mahipalet A, et. al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): pooled analyses after long-term follow-up in KEYNOTE-012. J Clin Oncol. 2016;34 (suppl; abstr 6012).

4. Tang C, Wang X, Soh H, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014;2:831–8.

5. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–95.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative study of [18F]AlF-PAI-PDL1p and [68Ga]Ga-PAI-PDL1p as novel PD-L1 targeting PET probes for tumor imaging;Bioorganic Chemistry;2024-10

2. Non-surgical Synergistic Interventions for the Treatment of Skin Cancer;Current Pharmaceutical Design;2024-06-20

3. Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer;Oral Oncology;2024-03

4. Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapy;Cancer Letters;2023-07

5. Pretreatment high cholesterol and low neutrophils predict complete pathological response after neoadjuvant short‑course radiotherapy followed by chemotherapy and immunotherapy in locally advanced rectal cancer;Oncology Letters;2023-06-07